Literature DB >> 2813280

Estimation of bioavailability on a single occasion after semisimultaneous drug administration.

M O Karlsson1, U Bredberg.   

Abstract

A method for determination of absorption rate and bioavailability was developed to reduce the influence of intraindividual variability and applied to the absolute intraperitoneal availability of lithium in the rat. In this method the test and the reference doses are given with a few hours' interval, and the resulting concentration-time data are analyzed by nonlinear regression. The bioavailability estimation by this approach was compared to that of the traditional method, with test and reference doses given on separate days. The mean estimates of availability were 1.035 +/- 0.109 (N = 7) and 0.984 +/- 0.052 (N = 11) for the traditional and the alternative method, respectively. Thus, the precision was better in the latter. Major influences of dose- or time-dependent kinetics of lithium on the availability estimates were excluded by the design used. The estimation of bioavailability was robust with respect to the choice of absorption and disposition model and the duration of sampling. The plasma clearance of lithium was 169 +/- 15 ml/hr/kg, with a terminal half-life of 5.0 +/- 0.5 hr (N = 5).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813280     DOI: 10.1023/a:1015939917646

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Kidney function and lithium concentrations of rats given an injection of lithium orotate or lithium carbonate.

Authors:  D F Smith; M Schou
Journal:  J Pharm Pharmacol       Date:  1979-03       Impact factor: 3.765

2.  The application of stable isotopes to studies of drug bioavailability and bioequivalence.

Authors:  R L Wolen
Journal:  J Clin Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.126

Review 3.  Methods for estimating drug bioavailability parameters. Part 3: Peculiarities of pharmacokinetic analysis in assessment of bioavailability.

Authors:  A A Firsov; V K Piotrovskii
Journal:  Pharmazie       Date:  1986-07       Impact factor: 1.267

4.  Diurnal variations in serum lithium and renal lithium clearance in rats given lithium as a single small dose or as multiple high doses.

Authors:  O V Olesen; K Thomsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-09

5.  Administration of lithium to rats by different routes.

Authors:  O V Olesen; M Schou; K Thomsen
Journal:  Neuropsychobiology       Date:  1976       Impact factor: 2.328

6.  The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug.

Authors:  A J Wood; G M Goodwin; R De Souza; A R Green
Journal:  Neuropharmacology       Date:  1986-11       Impact factor: 5.250

7.  Isotope effects: definitions and consequences for pharmacologic studies.

Authors:  A Van Langenhove
Journal:  J Clin Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.126

8.  Renal hemodynamics in conscious rats: effects of anesthesia, surgery, and recovery.

Authors:  L A Walker; M Buscemi-Bergin; M Gellai
Journal:  Am J Physiol       Date:  1983-07

9.  The pharmacokinetics of lithium in the brain, cerebrospinal fluid and serum of the rat.

Authors:  O Wraae
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

10.  The use of stable isotopes to prove the saturable first-pass effect of methoxsalen.

Authors:  J Schmid; A Prox; H Zipp; F W Koss
Journal:  Biomed Mass Spectrom       Date:  1980-11
  10 in total
  7 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.

Authors:  F Mesnil; C Dubruc; F Mentre; S Huet; A Mallet; J P Thenot
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

3.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

4.  Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Authors:  Margreke J E Brill; Anne van Rongen; Aletta P I Houwink; Jacobus Burggraaf; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

5.  Bioavailability of flumequine after semisimultaneous administration to veal calves.

Authors:  B A Meijer; K G Ceyssens; W T de Jong; B I de Grève
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

6.  Systemic availability and pharmacokinetics of nebulised budesonide in preschool children.

Authors:  L Agertoft; A Andersen; E Weibull; S Pedersen
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

7.  Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.

Authors:  A van Rongen; L Kervezee; Mje Brill; H van Meir; J den Hartigh; H-J Guchelaar; J H Meijer; J Burggraaf; F van Oosterhout
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.